

# MYKLEBOST, Ola – CURRICULUM VITAE

**Gender:** Male

**Year of birth:** 1955

**Nationality:** Norwegian

**E-mail:** ola.myklebost@ibv.uio.no

**Institutions:**

Oslo University Hospital, Radiumhospitalet

Inst Cancer Res., Dept Tumour Biology

University of Oslo, Inst. Biosciences



**Academic Qualifications:** *Doctor Philosophiae* (PhD), The Medical Faculty, University of Oslo 1990

## Present positions:

Senior scientist/Group leader, Institute for Cancer Research, OUS-Radiumhospitalet

Professor II, Institute for Biosciences, University of Oslo

Head Norwegian Cancer Genomics Consortium (cancergenomics.no)

Head Norwegian Sarcoma Consortium (NoSarC.org)

## Previous academic positions:

1983-85 Doctoral grant from Norwegian Research Council, at Institute for internal medicine, National Hospital, Oslo

1986-87 Doctoral grant from the Cancer Society, at Institute for internal medicine, National Hospital, Oslo

1995-99 Senior advisor to the National Health Board and secretary of their advisory board on the use of biotechnology in medicine, part time

2000-10 Head (alternating) Norwegian Genomics Consortium Oslo (FUGE Platform, genomics.no), University of Oslo

2005-14 Vice-Director, CAST Cancer Stem Cell Innovation Centre, OUS (cancerstemcell.no)

*International research positions:*

1982-83 Royal Society Exchange grant, at Biochemistry Dept, St Mary's Hospital Medical School, London

1985 Visiting scientist at Leiden University

1987 Visiting scientist at the EMBL, Heidelberg

## Selected International professional merits last 10 years:

Member of medical advisory board of the Liddy Shriver Sarcoma Initiative and editorial board of their newsletter 2012-.

Work package leader in the EU Network on Excellence on bone tumours, EuroBoNet.eu, 2006-11

Head organiser of the international conference “Frontiers in cancer stem cell research, - from basic science towards a cure” with 30 top international speakers and 270 participants, Oslo, 2009

Partner of the International Liposarcoma Consortium, 2010-

PI of the International liposarcoma consortium, Supported by the US Shriver Foundation 2014-

Norwegian Radium Hospital representative, the Scandinavian Sarcoma Group Working Group, 1997-

Member of the EURAMOS trial Translational studies group, 2008-

Member of the Medical Advisory Council of the Alan B. Slifka Foundation Sarcoma Program 2014-

**Scientific evaluations for foreign institutions (Projects or PhDs):** the UK Cancer Research Campaign (CRC), Biotechnology and Biological Sciences Research Council (UK), Dutch Cancer Society (KWF), Danish Strategic Research Council, Danish Board of Health, The Dutch Cancer Society, Wallenberg Consortium North, Italian Association for Cancer Research (AIRC), Karolinska Institutet, Helsinki University, Melbourne University, Leiden University.

## Supervision of PhD students

*Presently* under supervision: 3

*Completed* 7 as main supervisor

## Publications past five years 2010-15

in peer-reviewed journals: 41

**Total career publications** (Original): 141

**Total citations** 6646, average 36,

**H index** 40

## 42 publications in journals with impact > 5:

Bioinformatics (2), Biochem J (1), Biomaterials (1), Blood (1), BrJ Cancer (4), Cancer (2), Cancer Cell (1), Cancer Res (6), Clin Cancer Res (1), Drug Discovery Today (1), EMBO J (1), Int J Cancer (4), J Biol Chem (1), J Natl Cancer Inst (1), Leukemia (2), Mol Cancer (5), Nature Biotechnology (1), Lab on a Chip (1), Leukemia (2), Nature genetics (2), Nucl Acids Res (2), Oncogene (5), Oncotarget (3), PNAS (1), Science (1),

## On-going projects with external funding

**Personalized Cancer Medicine.** 35 MNOK, Norw. Research Council

**A national research and innovation platform for personalized cancer medicine.** 40 MNOK, Norw. Research Council

**NoSarC, – Norwegian Sarcoma Consortium. Towards individualized therapy for orphan cancer.** 7 MNOK Norwegian Cancer Society special charity “Krafftak mot Kreft”. 100% and 3x 20% Research technicians, National Competence Service for Sarcomas, Larssons Foundation, OUS

**Translational research in well- and de-differentiated liposarcoma – II.** Running costs 120 kUSD, Liddy Shriver Sarcoma Initiative

**Towards individualized therapy for orphan cancer.** Postdoc Helse Sørøst

**The role of let-7 microRNAs in cancers; Stemness, metabolism and epithelial-mesenchymal transition.** PhD Helse Sørøst

**Genomic aberrations in osteosarcomas.** PhD UiO Medical Faculty

**Mesenchymal Cancer Biology.** Technician, Running costs 150 kNOK Norwegian Cancer Society

**Biomarkers for response to Pembrolizumab in sarcoma (NoSarC.org).** 261 kUSD MSD

**Mesenchymal Cancer Medicine II.** Postdoc Norwegian Cancer Society

**Norwegian Stem Cell Centre: Methylation-dependent sumoylation of chromatin remodelers.** 3-500 kNOK/yr, Norw. Research Council

## Ola Myklebost PUBLICATION LIST last 4,5 years.

## Full papers.

- 
105. Namløs H, Kresse SH, Müller CR, Henriksen J, Sæter G, Bruland Ø, Holdhus R, Bjerkehagen B, Steen VM, Myklebost O (2012) Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern **Sarcoma** 2012, 1–12. doi:10.1155/2012/639038
106. Thomas DM, Wilhelm M, Cleton-Jansen AM, Dirksen U, Entz-Werlé N, Gelderblom H, Hassan B, Jürgens H, Koster J, Kovar H, Lankester AC, Lewis IJ, Myklebost O, Nathrath MHM, Picci P, Whelan JS, Hogendoorn PCW, Bielack SS (2012) Workshop report on the European Bone Sarcoma Networking Meeting: integration of clinical trials with tumor biology **Journal of Adolescent and Young Adult Oncology** Vol 1 DOI: 10.1089/jayao.2012.0005
107. Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Bürger H, Myklebost O, Hogendoorn PCW, Meza-Zepeda LA, Cleton-Jansen AM (2012) Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data **Genes Chromosomes Cancer** 51:696-706
108. Stratford EW, Castro R, Daffinrud J, Skårn M, Lauvrak SU, Munthe E, Myklebost O (2012) Characterization of liposarcoma cell lines for preclinical and biological studies **Sarcoma** 2012 doi:10.1155/2012/148614
109. Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, Bjerkehagen B, Kresse SH, Meza-Zepeda LA, Myklebost O (2012) Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma. **Cancer** DOI: 10.1002/cncr.27837
110. Namløs HM, Meza-Zepeda LA, Barøy T, Østensen IHG, Kresse SH, Kuijjer ML, Serra M, Bürger H, Cleton-Jansen AM, Myklebost O (2012) Modulation of the Osteosarcoma Expression Phenotype by MicroRNAs. **PLoS One** DOI: 10.1371/journal.pone.0048262
110. Kresse SH, Rydbeck H, Skårn M, Namløs HM, Barragan-Polania AH, Cleton-Jansen AM, Serra M, Liestøl K, Hogendoorn PCW, Hovig, E, Myklebost; O, Meza-Zepeda LA (2012) Integrative Analysis Reveals Relationships of Genetic and Epigenetic Alterations in Osteosarcoma. **PLoS One** DOI: 10.1371/journal.pone.0048262
- 
111. Doorn J, Hugo Fernandes H, Lee B, van de Peppel J, van Leeuwen JPTM, De Vries MR, Aref Z, Quax PHA, Myklebost O, Saris D, van Blitterswijk CA, de Boer J. (2013) A small molecule approach to engineering vascularized tissue. **Biomaterials** 34:3053-63. doi: 10.1016/j.biomaterials.2012.12.037 IF8
112. Bianchini L, Birtwisle L, Saâda E, Bazin A, Long E, Roussel JF, Michiels JF, Forest F, Dani C, Myklebost O, Birtwisle-Peyrottes I, Pedeutour F. (2013) Identification of PPAP2B as a novel recurrent translocation partner gene of HMGA2 in lipomas. **Genes Chromosomes Cancer** doi: 10.1002/gcc.22055
113. Stratford EW, Bostad M, Castro R, Skarpend E, Berg K, Høgset A, Myklebost O, Selbo PK (2013) Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcoma cells with stem-like properties and reduces tumorigenicity **Biochim Biophys Acta** 1830:4235–4243 doi:10.1016/j.bbagen.2013.04.033
114. Kuijjer ML, Peterse EFP, van den Akker BEWM, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PCW, Cleton-Jansen AM (2013) IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma **BMC Cancer** 13:245 doi:10.1186/1471-2407-13-245
115. Sandberg CJ, Altschuler G, Jeong J, Strømme KK, Stangeland B, Murrell W, Grasmø-Wendler UH, Myklebost O, Helseth E, Vik-Mo EO, Hide W, Langmoen IA (2013) Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt- signaling and a

fingerprint associated with clinical outcome **Experimental Cell Research**, doi  
10.1016/j.yexcr.2013.06.004

116. Nome T, Thomassen GOS, Bakken AC, Bruun J, Ahlquist T, **Lorenz S, Sun J**, Barros-Silva JD, **Myklebost O**, Teixeira M, **Meza-Zepeda LA**, Lothe RA, Skotheim RI (2013) Common fusion transcripts identified in colorectal cancer cell lines by high throughput RNA sequencing. **Translational Oncology** 6:546-53
117. **Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Namløs HM, Meza-Zepeda LA Myklebost O** (2013) Functional characterization of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes **Br. J. Cancer** 109:2228-36
118. **Skårn M, Barøy T, Stratford EW, Myklebost O** (2013) Epigenetic regulation and functional characterization of mir-142 in mesenchymal cells **PLoS One** 8: e79231.  
[doi:10.1371/journal.pone.0079231](https://doi.org/10.1371/journal.pone.0079231)
119. Behjati S, Tarpey PS, Presneau N, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gudem G, Davies H, Nik-Zainal S, Gamble J, Hardy C, Latimer C, Maddison M, Martin S, McLaren S, Mudie L, O'Meara S, Robinson B, Butler A, Teague JW, Kathri B, Halai D, **Myklebost O**, Baumhoer D, Jundt G, Tirabosco R, Amary F, Futreal PA, Stratton MR, Campbell PJ, Flanagan AM (2013) Distinct H3F3A and H3F3B driver variants define chondroblastoma and giant cell tumour of bone **Nat Genet** 45:1479-82. [doi: 10.1038/ng.2814](https://doi.org/10.1038/ng.2814)
120. **Stratford EW, Daffinrud J, Munthe E, Castro R**, Waaler J, Krauss S, **Myklebost O** (2013) The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. **Cancer Medicine** 3:36-46 [doi: 10.1002/cam4.170](https://doi.org/10.1002/cam4.170)
- 
121. **Chilamakuri CSR, Lorenz S, Madoui MA**, Vodák DA, Sun J, Hovig W, **Myklebost O, Meza-Zepeda LA** (2014) Performance Comparison of four exome capturing systems for deep sequencing **BMC Genomics** 15:449 [doi:10.1186/1471-2164-15-449](https://doi.org/10.1186/1471-2164-15-449)
122. **Barøy T, Kresse SH, Skårn M, Stabell M, Castro R, Lauvrak S**, Llombart-Bosch A, **Myklebost O, Meza-Zepeda LA** (2014) Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma model. **Molecular Cancer** 13:93, [doi:10.1186/1476-4598-13-93](https://doi.org/10.1186/1476-4598-13-93)
- 123 **Håkelien AM, Bryne JC, Harstad KG, Lorenz S**, Paulsen J, **Sun J**, Mikkelsen TS, **Myklebost O, Meza Zepeda LA** (2014) The regulatory landscape of osteogenic differentiation. **Stem Cells** 32:2780-93 DOI: 10.1002/stem.1759
- 124 **Skårn M, Noordhuis P**, Wang MY, Veuger MJT, **Kresse SH, Egeland EV**, Micci F, **Namløs HM, Håkelien AM, Olafsrud SM, Lorenz S**, Haraldsen G, Kvalheim G, **Meza-Zepeda LA, Myklebost O** (2013) Generation and characterisation of an immortalised human bone marrow derived mesenchymal stromal cell line. **Stem Cells and Development** [doi:10.1089/scd.2013.0599](https://doi.org/10.1089/scd.2013.0599)
- 125 Anninga JK, Cleton-Jansen AM, Hassan B, Amary MF, Baumhoer D, Blay JY, Brugieres L, Ferrari S, Jürgens H, Kempf-Bielack B, Kovar H, **Myklebost O**, Nathrath M, Picci P, Riegman P, Schilham MW, Soliman R, Stark DP, Strauss A, Sydes M, Tarpey P, Thomas D, Whelan J, Wilhelm M, Zamzam M, Gelderblom H, Bielack SS (2014) Workshop Report on the 2nd Joint ENCCA/EuroSARC European Bone Sarcoma Network Meeting: Integration of Clinical Trials with Tumour Biology. **Clinical Sarcoma Research** 4:4, [doi:10.1186/2045-3329-4-4](https://doi.org/10.1186/2045-3329-4-4)
- 126 **Stratford EW, Myklebost O** (2014) TRAP1 is a novel interaction partner of PML, localised with PML in nuclear bodies and relocating with PML to the cytoplasm following stress **Annual research and review in biology** 4:3026-36
127. **Wennerström AB**, Lothe IMB, Sandhu V, Kure E, **Myklebost O, Munthe E** (2014) Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines. **PLoS One** 9:e103873

128. Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, Van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP, Nik-Zainal S, Alexandrov L, Behjati S, Yates LR, Bolli N, Mudie L, Hardy C, Martin S, McLaren S, O'Meara S, Andreson E, Maddison M, Gamble S, ICGC Breast Cancer Group, **ICGC Bone Cancer Group**, ICGC Prostate Cancer Group, Foster C, Warren AY, Whitaker H, Brewer D, Eeles R, Cooper C, Neal D, Lynch AG, Visakorpi T, Isaacs WB, van't Veer L, Caldas C, Desmedt C, Sotiriou C, Aparicio A, Foekens JA, Eyfjörd JE, Lakhani SR, Thomas G, **Myklebost O**, Span PN, Børresen-Dale AL, Richardson AL, van de Vijver M, Vincent-Salomon A, van den Eynden GG, Flanagan AM, Futreal PA, Janes SM, Bova GS, Stratton MR, McDermott U, Campbell PJ (2014) Extensive transduction of non-repetitive DNA mediated by L1 retrotransposition in cancer genomes **Science** Vol. 345 no. 6196:1251343 DOI: 10.1126/science.1251343
129. Garsed DW, Marshall OJ, Corbin VDA, Hsu A, di Stefano L, Schröder J, Li J, Feng ZP, Kim BW, Kowarsky M, Lansdell B, Brookwell R, **Myklebost O**, **Meza-Zepeda LA**, Holloway AJ, Pedeutour F, Choo KHA, Damore MA, Deans AJ, Papenfuss AT, Thomas DM (2014) Architecture and Evolution of a Cancer Neochromosome, **Cancer Cell** 26:653-667
- 
130. **Serguienko A, Grad I, Wennerstrøm AB, Meza-Zepeda LA**, Thiede B, **Stratford EW, Ola Myklebost O, Munthe E** (2015) Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA **Oncotarget** In press
131. Naderi EH, Ugland H, **Myklebost O**, Sandnes DL, Torgersen ML, Josefsen D, Ellen Ruud E, Naderi S, Blomhoff HK (2015) Bone marrow stroma-derived PGE<sub>2</sub> protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death, **Mol Cancer** in press doi:10.1186/s12943-014-0278-9
132. Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, **Myklebost, Ola**, Nakken S, Vodak D, **Meza-Zepeda LA**, Hovig E, Sandvik A, Wader KF, Misund K, Sundan A, Aarset H, Waage A (2015) Clinical and biological implications of BRAF V600E mutation in multiple myeloma. **Blood Cancer J** in press
133. Safavi S, Järnum S, Vannas C, Udane S, Jonasson E, Tomic TT, Grudevik P, Fagman H, Hansson M, Kalender Z, Jauhainen A, Dolatabadi S, **Stratford EW, Myklebost O**, Eriksson M, Stock ES, Ståhlberg A, Åman P (2015) HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. **Oncotarget** In press
134. Ju YS, Tubio JMC, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M, ICGC Prostate Cancer Working Group, ICGC Bone Cancer Working Group, ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Ta M, Lee M, van't Veer LJ, Tan BKT, Aparicio S, Span PN, Martens JWM, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, **Myklebost O**, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PM, Stratton MR (2015) Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells **Genome Res** 25:814-24. doi: 10.1101/gr.190470.115.

#### Other articles from my group:

- S30 Chymkowitch P, Eldholm V, **Lorenz S**, Zimmermann C, Lindvall J, Bjørås M, **Meza-Zepeda LA**, Enserink JM (2012) Cdc28 kinase activity regulates the basal transcription machinery at a subset of genes. **Proceedings of the National Academy of Sciences USA** (PNAS), 109 (26) 10450-10455 doi:10.1073/pnas.1200067109
- S31 Reikvam DH, Derrien M, Islam R, Erofeev A, Grcic V, Sandvik A, Gaustad P, **Meza-Zepeda LA**, Jahnsen FL, Smidt H, Johansen FE (2012) Epithelial-microbial crosstalk in polymeric Ig receptor

deficient mice **Eur J Immunol**, 42, 2959-70

- S32** Bjørnstad LG, Meza TJ, Otterlei M, **Olafsrud SM, Meza-Zepeda LA**, Falnes PØ (2012) Human ALKBH4 interacts with proteins associated with transcription **PLoS One**, 7 (11), e49045
- 
- S33** Wang P, Gao Q, Suo Z, **Munthe E**, Solberg S, Ma L, Wang MY, Westerdaal NAC, Kvalheim G, Gaudernack G (2013) Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines **PLoS One** in press
- S34** Herlofsen SR, **Bryne JC**, Høiby T, Wang L, Issner R, Zhang X, Coyne MJ, Boyle P, Gu H, **Meza-Zepeda LA**, Collas P, Mikkelsen TS, Brinchmann JE (2013) Genome-wide map of quantified epigenetic changes during in vitro chondrogenic differentiation of primary human mesenchymal stem cells **BMC Genomics**, 14, 105
- S35** Qu S, **Olafsrud SM, Meza-Zepeda LA**, Saatcioglu F (2013) Rapid gene expression changes in peripheral blood lymphocytes upon practice of a comprehensive yoga program **PLoS One**, 8 (4), e61910
- S36** Schee K, **Lorenz S**, Worren MM, Günther CC, Holden M, Hovig E, Fodstad O, **Meza-Zepeda LA**, Flatmark K (2013) Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer **PLoS One**, 8 (6), e66165
- 
- S37** Tran D, Verma K, Ward K, Diaz D, Kataria E, Torabi A, Almeida A, Malfoy B, Stratford EW, Mitchell DC, Bryan BA (2014) Functional Genomics Analysis Reveals a MYC Signature Associated with a Poor Clinical Prognosis in Liposarcomas **Am J Pathol** *n press doi:10.1016/j.ajpath.2014.11.024*
- 
- S38** Chymkowitch P, Nguéa P A, Aanes H, Koehler CJ, Thiede B, **Lorenz S, Meza-Zepeda LA**, Klungland A, Enserink JM (2015) Sumoylation of Rap1 mediates the recruitment of TFIID to promote transcription of ribosomal protein genes **Genome Res**, 25 (6), 897-906 PubMed 25800674
- S39** Fernandez-Cuesta L, Sun R, Menon R, George J, **Lorenz S, Meza-Zepeda LA**, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z et al. (2015) Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. **Genome Biol**, 16, 7 PubMed 25650807

## Theses

- MSc Eivind Valen Egeland 2011** Osteogenic differentiation of mesenchymal stem cells: identification of potential regulators. **University of Oslo**
- MSc Tale Barøy 2011** Characterization of LSAMP, a novel candidate tumor suppressor gene in osteosarcomas. **University of Oslo**
- MSc Anastassia Serguienko 2012** Targeting cancer stem cells through *let7* miRNAs. **University of Oslo**
- PhD Heidi Namløs 2013** Molecular biological characterization of sarcomas and sarcoma development. **University of Oslo**
- PhD Hege Ohnstad 2013** Biologically adapted therapy against mesenchymal tumours. **University of Oslo**
- PhD Magne Skårn 2014** MicroRNA biology in mesenchymal models and cancer. **University of Oslo**
- MSc Marie Elise Engkvist 2015** Novel mechanisms of tumour suppression by the miR-34 family. **University of Oslo**

## Reviews, reports and scientific correspondence:

- R2. Myklebost O** (1996) First for biotech. **Nature** 384:208
- R4. Myklebost O** (1998) GLI gene and rhabdomyosarcoma. **Nature Medicine** 4:869

- R15 Myklebost O (2004)** Putting Norway on the gene-therapy map. Letter to the Editor of **Nature**, **429**:129
- R17** Skotheim RI, **Meza-Zepeda LA**, Hovig E, Lønning PE, Lothe RA, **Myklebost O (2012)** Genomsekvensering for persontilpasset kreftmedisin. **Tidsskr. Nor. Lægeforening** 132:2406-8
- R18** Thomas D, **Myklebost O, Meza-Zepeda LA (2013)** Research in Well-Differentiated and Dedifferentiated Liposarcoma ESUN - A Periodical for the Sarcoma Community, Volume 10, Number 1
- R19 Myklebost O (2015)** Personalized cancer therapy for soft tissue sarcomas: progress and pitfalls (Review) **Personalized Medicine** *In press*
- R20 Myklebost O** Norwegian Cancer Genomics Consortium, a platform for research on personalized cancer medicine in a public health system. **Drug Discovery Today**: Special issue on Stratified Medicine *In press*

### Other

- Hovig E, **Myklebost O (2012)** Mister gode hoder til oljebransjen (Intervju), **Aftenposten**, **20130102**
- Myklebost O (2011)** Henrietta Lacks udødelige liv (intervju) **NRK P2 Ekko** 20111007
- Myklebost O (2012)** Intervju om medisinske gjennombrudd **VG** 20121126
- Myklebost O (2012)** Intervju om persontilpasset kreftmedisin **Dagens medisin** 20121016
- Myklebost O (2012)** Intervju om persontilpasset kreftmedisin **VG** 20120413
- Lothe RA, **Myklebost O (2012)** Intervju om persontilpasset kreftmedisin **NRK TV P1 Morgennytt** 20120208
- Myklebost O (2012)** Reading cancer's blueprint (Interview) **Nature Biotechnology** 20120701
- Myklebost O (2012)** Norway to bring cancer tests to the clinic (Interview) **Nature Web** 20120202
- Myklebost O (2012)** Intervju om Norsk kreftgenomikkonsortium **NRK Ekko**
- Forskning.no** Omtale av FUGE-konsortiet Nuclear Programming
- NRK Forskningsweb** Interview
- Dagens Medisin** Interview
- invited speaker OCC, Dagens Medisin, UiB
- Deutsche Sarkomkonferenz** invited speaker
- VG** 3x Interview
- Kreftforeningen: **Sammen mot kreft** Nr 4 (2012) s18-19 "På vei mot persontilpasset kreftmedisin" Intervju
- Kreftforeningen** Benyttet som frontfigur til **juleinnsamlingen** 2012
- Invited speaker **Personalized Medicine Conference**, Harvard Nov 2012
- Biotech Scandinavia** Dec 12, - Intervju "Norway invests in personalized cancer care"
- Forskning.no** "Storsatsing på bedre kreftbehandling" Intervju om NFR-prosjektene om Persontilpasset kreftmedisin Mars 2013

**Vi Menn; Vitenskap og historie.** Kreftforskning; Kan kampen vinnes? Intervju og omtale av persontilpasset kreftmedisin. 03 2013

**Forskning.no** "Kartlegger kreftgenene" Intervju om NFR-prosjektene om Persontilpasset kreftmedisin Mai 2013

**Forskning.no** "Beregner seg frem til ny kreftbehandling" Intervju om NFR-prosjektene om Persontilpasset kreftmedisin Nov 2013

**NRK P1 Norgesglasset** 26/2-14 "En ny generasjon kreftmedisin" Intervju

**Verdens Gang** Kommentar «Dødstest» kan forutsi risiko for å dø i løpet av fem år. Norsk forsker: - Grundig studie. **VG.no** 27/2-14

**Vi over 60.** "Muligheter med livets strekkode" Intervju og omtale av persontilpasset kreftmedisin. Juli 2014

**Ola Myklebost: "Gener og kreft" ("Genes and Cancer").** I Dag O. Hessen, Thore Lie og Nils Chr. Stenseth (red.): *Mendels arv - genetikkens æra*, 2015, s 247-263.

**Ola Myklebost: "Cancer Who-done-it"** foredrag om "etterforskning" av kreftsvulster på **Article Biennalen 2015**, Stavanger kunstmuseum, feb 2015.

**Ola Myklebost** "It's All About the Genome" Interview in **Handelsblatt Global Edition** (Germany) 29.04.2015

**A-Magasinet:** "Jakten på en kreftkur" ("The hunt for a cancer cure"). 9 pages feature article on the NoSarC project in the largest Norwegian Newspaper (**Aftenposten**) weekend magazine. March 19th 2015

**Ola Myklebost: Gener og kreft.** I Dag O. Hessen, Thore Lie og Nils Chr. Stenseth (red.): *Mendels arv - genetikkens æra*, 2015, s 247-263.

**Ola Myklebost,** Per Eystein Lønning, Bjørn Tore Gjertsen og Ragnhild Lothe. Bør hver kreftpasient bli et eget forskningsprosjekt? Kronikk i **Aftenposten** 12.8.15

**Ola Myklebost** Intervju i **Dagens Medisin** (ifbm Arendalsuka) "Helseforetakene driver beskyttede industribedrifter" Om svak satsing på fagutvikling og utprøvende behandling. Aug. 2015